Fredun Pharmaceuticals Limited announced on May 15, 2026, the launch of 'DAULCÉL', its premium wellness and longevity-focused brand developed to cater to the growing demand for preventive healthcare, healthy aging, and lifestyle-oriented wellness solutions. The launch marks a strategic step in the company's expansion into innovation-led and future-focused healthcare segments, leveraging its existing formulation and healthcare expertise.

Brand Overview and Strategic Positioning

DAULCÉL is positioned as a premium wellness platform centered on quality, innovation, and evolving consumer wellness needs. The brand addresses the increasing global focus on vitality, wellness optimization, recovery-focused healthcare, and long-term healthy living through science-oriented wellness solutions. The initiative complements Fredun Pharmaceuticals' existing pharmaceutical and healthcare capabilities while creating new opportunities within specialized wellness and longevity-driven categories.

The following table outlines the key parameters of the DAULCÉL brand launch:

Key Highlights of the Launch

The DAULCÉL brand launch encompasses several strategic dimensions:

• First premium NAD+ based wellness offerings introduced in India's emerging longevity and cellular wellness segment
• Strategic expansion into preventive and lifestyle-oriented healthcare
• Focused on wellness, vitality, and healthy aging solutions
• Science-oriented and innovation-driven brand approach
• Expansion into emerging and high-growth wellness categories
• Strengthening Fredun's specialty healthcare and wellness portfolio
• Leveraging the company's formulation and healthcare expertise
• Focused on differentiated, quality-driven wellness offerings

DAULCÉL's initial portfolio is designed around premium wellness solutions aligned with the growing demand for advanced wellness, cellular vitality, and healthy lifestyle management. The brand aims to combine innovation, quality-focused development, and consumer-centric healthcare experiences to establish a differentiated presence within the evolving wellness market.

Management Commentary

Commenting on the development, Mr. Fredun Medhora, Managing Director, said: "Daulcé reflects our focus on building future ready healthcare capabilities. Preventive health and longevity are becoming increasingly relevant, and we see strong potential in delivering science driven solutions that address these needs in a meaningful way."

About Fredun Pharmaceuticals Limited

Fredun Pharmaceuticals Limited is a healthcare and pharmaceuticals company offering a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs), and narcotics. The company is also engaged in the manufacturing of dietary/herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products, along with animal healthcare products. It primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries, and Latin America.

The company's financial performance for FY25 is summarised below:

Fredun Pharmaceuticals Limited has announced the strategic launch of "HORMONE RANGE PRODUCTS", a premium specialty therapeutics brand focused on longevity, hormone health, recovery science, and human performance solutions. The announcement was made on 15th May, 2026, under Regulation 30, marking the company's entry into a rapidly expanding, high-value healthcare segment driven by increasing global demand for preventive, performance-oriented, and precision-based therapeutics.

The hormone range products are built on a doctor-led, ethical, and evidence-backed pharmaceutical model, combining clinical credibility with a digital-first patient and doctor engagement ecosystem. The range is designed to address the growing shift from traditional disease management towards healthy lifespan optimization, preventive care, and advanced performance therapeutics.

Strategic Highlights

The launch encompasses several strategic dimensions that position Fredun Pharmaceuticals in the specialty therapeutics space. Key highlights of the initiative include:

• Strategic expansion into high-growth longevity and specialty hormone therapeutics
• Doctor-led and evidence-backed platform focused on clinical outcomes
• Premium positioning in hormone health, recovery science, and performance care
• Digital and pharma hybrid model enabling end-to-end patient engagement
• Focused on precision-driven, high-margin, and differentiated therapeutic categories
• Strengthening Fredun Pharmaceuticals' innovation-led specialty pharma portfolio
• The range will work in conjunction with the company's existing protein supplement range, enabling a more comprehensive approach towards preventive healthcare, wellness, and performance therapeutics

Initial Product Portfolio

The initial portfolio includes therapies and formulations across key hormone and performance therapeutic categories. The following table outlines the core product focus areas:

The platform is further supported by protocol-driven patient monitoring, doctor engagement, and direct-to-patient fulfillment capabilities designed to improve treatment continuity and patient adherence.

Core Business and Growth Drivers

The brand leverages Fredun Pharmaceuticals' established strengths in pharmaceutical formulation development, quality-focused manufacturing, and global distribution capabilities. The core business and growth drivers underpinning the launch are:

• Premium, science-driven therapeutic positioning
• Focus on hormone optimization and preventive healthcare
• Digital-led patient acquisition and retention strategy
• Specialised formulations with strong clinical orientation
• Direct-to-patient engagement and subscription-based continuity model
• Expansion into emerging high-growth healthcare categories

Management Commentary

Commenting on the development, Mr. Fredun Medhora, Managing Director, Fredun Pharmaceuticals Limited, stated: "The launch of our hormone range products represents a significant milestone in our journey towards building a more specialised and future-ready pharmaceutical portfolio. As we move up the value chain, our focus is on entering segments that demand high scientific rigor, clinical validation, and manufacturing excellence. This range reflects our vision by bringing together medical expertise and evidence-based formulations to create a credible presence in hormone and performance therapeutics."

About Fredun Pharmaceuticals Limited

Fredun Pharmaceuticals Limited is a healthcare and pharmaceuticals company offering a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs), and narcotics. The company is also engaged in the manufacturing of dietary and herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products, along with animal healthcare products. The company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries, and Latin America. The following table summarises the company's key financial metrics for FY25: